TheraCryf PLC (TCF)

Industry Biotechnology

This stock can be held in an Investment ISA, SIPP and Investment Account

Sell

0.18p

Buy

0.22p

arrow-up0.008p (+4.00%)

Prices updated at 19 Dec 2025, 12:29 GMT

Prices minimum 15 mins delay

Prices in GBX

Evgen Pharma PLC is a clinical stage drug development company focused on cancer and neurological disease. Its pipeline is based on Sulforadex technology which includes synthetic and stabilized analogues of sulforaphane.

FTSE All-Share

-0.03%

LSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

	0.22p - 0.19p
	1.25p - 0.18p
	-
	4.30m
	-
	100,000
	203,939
	0.90
	3,102,653.73
	2.72
	2,129.62m
	GB00BSVYN304
	0.00
	-

Please note that past performance is not a reliable indicator of future returns. Pre-sale Illustration.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.